Exosomes are nano-scale messengers loaded with bio-molecular cargo of RNA, DNA, and Proteins. As a master regulator of cellular signaling, stem cell (both normal, and cancer stem cells) secreted exosome orchestrate various autocrine and paracrine functions which alter tumor micro-environment, growth and progression. Exosomes secreted by one of the two important stem cell phenotypes in cancers a) Mesenchymal stem cells, and b) Cancer stem cells not only promote cancerous growth but also impart therapy resistance in cancer cells. In tumors, normal or mesenchymal stem cell (MSCs) derived exosomes (MSCexo) modulate tumor hallmarks by delivering unique miRNA species to neighboring cells and help in tumor progression. Apart from regulating tumor cell fate, MSC-exo are also capable of inducing physiological processes, for example, angiogenesis, metastasis and so forth. Similarly, cancer stem cells (CSCs) derived exosomes (CSC-exo) contain stemness-specific proteins, self-renewal promoting regulatory miRNAs, and survival factors. CSC-exo specific cargo maintains tumor heterogeneity and alters tumor progression. In this review we critically discuss the importance of stem cell specific exosomes in tumor cell signaling pathways with their role in tumor biology.
Stem cells are undifferentiated, self-renewing, clonogenic subpopulations present in various adult tissues and display multi lineage differentiation potential. As tumor tissues are considered pathological organs, 1 it is reported that they harbor pathological or cancer stem cells (CSCs). [2] [3] [4] CSCs regulate tumor growth, and progression in multiple cancer types. [5] [6] [7] [8] Conventionally, CSCs are non-homing, resident tumor stem cell types which promote angiogenesis, drug resistance and metastasis by local interactions with various cancer cell populations. 6, [9] [10] [11] In addition to CSCs, tumor homing or motile mesenchymal stem cells are often present in various malignancies. MSCs are multipotent stem cells in various adult (e.g., adipose tissue, bone marrow) and embryonic (Wharton's Jelly of umbilical cord) tissues which have been studied extensively for their potential role in regenerative medicine. [12] [13] [14] Investigations in various tumors have shown that MSCs can behave antagonistically-they can either promote, or inhibit tumor growth. Despite the lack of consensus about MSC functions in tumors, it is widely established that tumor migratory MSCs play complex functions including modulate of tumor growth, and progression. [15] [16] [17] [18] [19] [20] Similar to CSCs, MSCs are multipotent, self-renewing cell types and a vital component of complex tumor-microenvironment. Both CSCs and MSCs are known to secrete nanoscale vesicles or exosomes. Exosomes are 30-100 nm membrane vesicles, released from many cell types in tumors including but not limited to cancer cells, endothelial cells, and immune cells. [21] [22] [23] Exosome cargo mainly contains DNA, proteins, lipids, mRNAs and miRNAs. Mechanistically, exosome released from cell-of-origin facilitates intercellular communication either by direct cellular uptake or internalization via a target cell receptor in recipient cell. 24, 25 The horizontally transferred exosomal constituents, for example, DNA, mutated DNA, miRNA, mRNA prime recipient cell type for effecter functions and activate downstream signaling. For example, exosomal transfer of PTEN decreases cell proliferation in recipient cells. 26 In line, stem cell derived exosomes carry pluripotent transcription factors such as Nanog, Oct-4 and Wnt family proteins which can promote self-renewal, stemness in recipient cells via changes in cellular plasticity. 27, 28 Importantly, since both CSCs, and MSCs are known regulators of different tumor hallmarks, it is plausible that MSCs, CSCs derived exosomes may as well prime tumor microenvironment and modulate tumor functions. In this review, we focus on the role of two prominent stem cell populations-CSCs, and MSCs-derived exosomes in regulating tumor pathobiology.
Mesenchymal Stem Cell Derived Exosomes
Mounting evidences suggest that MSC-exo carry regulatory proteins, mRNA, and miRNA which are delivered to a spectrum of recipient cell types in cancer, for example, tumor cells, tumor associated fibroblasts, endothelial cells and so forth. The dynamic interaction signaling initiated by MSCexo can profoundly alters phenotype of the recipient tumor/ stromal cells. MSC-exo are shown to exert both pro-tumorigenic 17, 29, 30 and anti-tumor 31, 32 functions in recipient cells. Here, we will discuss MSC-exo mediated modulation of tumor cell features.
Growth effects of MSC-exo on tumor cells-pro survival and apoptotic roles
Tumor cell growth is regulated by various growth factor receptor, for example, EGFR, PDGFR, MET and so forth mediated signaling. Activation or phosphorylation of intracellular kinase domain of these receptors triggers downstream growth promoting signaling via Akt, PKC/PKB and MAP kinase pathways which leads to tumor cell proliferation. In an ex vivo study in gastric cancer cell model, MSC-exo promoted migration and proliferation of gastric cancer cells via Akt, and PKB activation. 33 Similarly, MSC-exo promoted murine tumor growth in a subcutaneous tumor model of gastric cancer cell line-SGC-7901. In a gain-of-function study, intra-tumoral injection of exosome derived from engineered MSC over expressing mir146b reduced glioma growth in a rat brain tumor model.
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Whether pro-, or anti-tumor nature of MSC-exo, these studies underscore the importance of MSC-exo in cancerous growth and define emergence of new paradigms in tumor biology.
Migratory phenotype and epithelial-mesenchymal transition (EMT) induction by MSC-exo
Tumor cell migration is fundamental to metastasis and invasion of surrounding normal tissue by cancer cells. MSC-exo are capable of inducing migratory phenotype in tumor cells. Epithelial tumor cells upon trigger may lose polarity and acquire mesenchymal or migratory phenotype through a process of epithelial-mesenchymal transition (EMT). Shi et al. showed that treatment of MSC-exo induced EMT markers in nasopharyngeal carcinoma cells via FGF19-FGFR4 axis. 38 Likewise, MCF-7 cells were shown to acquire a migratory phenotype after in vitro treatment with MSCexo. 39 Often, biomolecules secreted in exosomes are functional in recipient cells. Yang et al. showed that MSC-exo contained matrix metalloproteinase-2 or MMP-2 enzyme which remained functional upon exosome uptake in MCF-7 (breast cancer) and SCCOHT-1 (ovarian cancer) cells as studied in a gelatinase assay 40 (Table 1) . Indeed, exosomal export and uptake of extracellular matrix degrading enzyme, for example, MMP-2 can alter invasion potential of tumor cells and favourably condition stroma. Such interactions can not only generate new phenotypes (e.g., migratory nature) but also impart acquired phenotypic heterogeneity in tumors.
Chemoresistant phenotype induction by MSC-exo
One of the reasons why tumors are not treatable is due to emergence of drug/chemoresistance in cancer cells. Chemoresistance in cancer cell could be intrinsic or acquired. MSCexo induced acquired chemoresistance is one potential mechanism for generation of therapeutic heterogeneity in tumors. In a gastric cancer model, MSC-exo increased resistance to 5-FU by enhancing multidrug resistance proteins expression followed by downstream activation of Raf/MEK/ERK pathways. 41 Cellular cycling is important physiological property of tumor cells and fast cycling clones are often killed by therapy. Interestingly, Bliss et al. showed that MSC-exo can trigger quiescent phenotype in breast cancer cells via mutual interactions and subsequent delivery of specific miRNAs. 42 It was found that mir-222/223 containing MSC-exo induced dormancy and thereby conferred drug resistance in breast cancer cells. Likewise, MSC-exo mediated delivery of miR-9 to glioblastoma (GBM) cells made them resistant to temozolomide drug by inducing drug transporters expression in recipient cells. 17 These reports suggest that MSC-exo not only condition tumor microenvironment for cell-cell interactions but are also vital players in generating functional tumor heterogeneity.
Angiogenesis modulation of MSC-exo
Like the controversial role of MSC-exo on tumor cell growth, it is still not well understood how MSC-exo contribute to tumor angiogenesis. Similar to tumor-dependent role of MSC-exo is cancer cell growth, studies in different tumors have shown antagonistic functions of MSC-exo on angiogenesis. For example, MSC-exo downregulated VEGF expression in breast cancer cells both in vitro and in vivo. 43 In this study, VEGF targeting miR-16 was found to be enriched in MSC-exo and potentially contributed to anti-angiogenic functions of MSC-exo. Conversely, MSC-exo treatment in a gastric cancer cell line promoted VEGF expression and enhanced tumor growth in xenografts. 29 Such disparity or opposing angiogenesis effects may likely arise due to multiple factors, for example, exosome harvesting conditions (confluency of MSCs during exosome harvesting) and MSC growth dependent regulation of pro-, anti-miRNA export in exosomes etc. Another study in human umbilical vein endothelial cells (HUVECs) showed that a pro-angiomiR miR30-b is exported in MSC-exo and upregulates angiogenic potential of HUVEC cells upon MSC-exo uptake. 44 Horizontal transfer of functional exosomal receptor-ligand molecules between MSCs-endothelial cells can create a more complex microenvironment favouring angiogenesis (Fig. 1, Table 1 ). In line, Gonzalez-King et al. showed that hypoxic MSC derived exosomes elevated angiogenesis in endothelial cells by horizontal transfer of Jagged-1, and by activating downstream Notch pathway. 45 Surprisingly, exosome blocking in Jagged 1 over expressing tumors could serve as a potential anti-angiogenic therapeutic strategy.
Cancer Stem Cell Derived Exosomes
Cancer stem cells (CSCs) are considered as fundamental building blocks in heterogeneous tumor tissues. CSCs are self-renewing, multipotent tumor cells which contribute to tumor progression, therapy resistance, metastasis, and tumor relapse. 7, 10, 11, 46, 47 CSCs are characterized in various in vitro and in vivo functional assays such as self renewal assay, differentiation assay, and tumorigenicity assay. 7, 8, 46 Often, various cell surface markers, for example, CD133, CD44, CD24 are used to characterize or isolate CSC populations from non-stem cancer cells in a culture. 48 Due to therapy resistance nature of CSCs, they have been studied extensively in almost all of cancer types. Likewise, CSCs derived exosomes (CSC-exo) are also emerging as potent tumor microenvironment regulators. Here, we will discuss various tumor features regulated by CSC-exo
Angiogenesis, immune modulation by CSC-exo
Glioblastoma (GBM) is highly vascularized brain tumor which shows acute immune suppression. 49 Domenis et al.
showed that GBM CSCs suppressed tumor immunity by exosome mediated complex interactions between Monocytes and T cells. Interestingly, it is only in presence of monocytes that CSC-exo were able to inhibit T cells via IL-10 specific secretion in monocytes. 50 The study revealed a much complex role of CSC-exo in GBM immunosuppression. Next, Sun et al. ectopically expressed miR-21 (an over expressed miRNA in GBM) in a CSC culture model and exosomes derived from donor CSCs increased angiogenic potential of the endothelial cells. 51 These studies put forth new questions as to how exosomal oncomiRs mediate angiogenesis and redefine tumor microenvironment conditions. Furthermore, miR-1 overexpressing stem-like GBM cell derived extracellular vesicles reduced endothelial tube formation, and migration potential of tumor cells 52 (Table 1 ). This study suggests that extracellular vesicles from GBM CSCs can favourably condition tumor microenvironment during tumor growth, progression. In addition to functional miRNAs, proangiogenic mRNA VEGFA is also secreted in GBM CSC exosomes and promotes permeability, and angiogenic potential of endothelial cells. 53 Similar to GBM CSC exosome, exosomes obtained from CD1051 renal cancer CSCs activated endothelial cells and enhanced their vessel formation ability in addition to priming a pre-metastatic niche for tumor cells. 54 Next, CD901 liver CSC released exosomes stimulated angiogenesis via a non-coding RNA (lncRNA) H19 mediated upregulation of VEGFR1 in endothelial cells. 55 These effects were found to be associated with exosomal export of specific RNA species in CSCs. Though, in most of the CSCendothelial interaction studies exosomal miRNAs appears to be fundamental biological response modifier, it is yet to be identified if CSC-specific receptor proteins are exported into CSC-exo and regulate angiogenesis process.
Tumor heterogeneity maintenance by CSC-exo
CSCs are master regulators of tumor microenvironment. From influencing tumor immunity to drug resistance, and invasion, CSCs' role in tumor biology is ever emerging. 6, 8, 56, 57 CSCs phenotype is dynamic and maintained in close association w.r.t. their surrounding tumor microenvironment in vivo. Though, tumor cells maintain their genetic and phenotypic identity in growing tumors by expressing specific set of genes, nevertheless, cellular cross-talk via exosomes can create a "dynamic tumor heterogeneity". Interestingly, Li et al. showed in a breast cancer model that CD49f1/CD441/CD242 breast cancer CSC derived extracellular vesicles modulate tumor microenvironment. 58 The study showed that chemo preventive agent sulforaphane treatment enhanced miR-140 secretion in CSC extracellular vesicles which in turn prevented stemness in recipient cells. The study highlighted a more complex microenvironment regulation via CSC exosomes. In prostate cancer, a high throughput miRNA screen revealed that miR-139 and miR-183 were enriched in prostate CSC-exo and promoted cell proliferation, migration in prostate fibroblast cells. 59 These studies indicate that CSC-exo mediated tumor stroma modulation is a vital aspect of exosome singling in cancer. Additionally, various CSC-specific signaling proteins are also exported in exosomes. For example, Wnt/b-catenin pathway is crucial regulator of CSC phenotype in many cancers. 28, [60] [61] [62] [63] [64] [65] It is shown that betacatenin is released in exosomes. 66 Although not reported in a CSC model, the study proposed a possibility of Wnt activation in surrounding tumor cells by uptake of CSC-specific exosomes. Similarly, various CSC-specific molecules are shed out in exosomes which includes (i) transcriptional activators-Notch pathway components (Jagged 1, Dll4), pluripotancy/stem cells factors (Oct4), (ii) functional enzymes (ALDH) and (iii) Phenotypic surface receptors (CD133, CD44). 67, 68 Taken together, is plausible that CSC exosomes containing these molecules can generate transient or dynamic tumor heterogeneity in the neighboring tumor microenvironment 69 ( Fig. 1 ). More so, the immediate and spatiotemporal effects of such interactions are yet to be explored and may lead to development of new therapeutic strategies in cancers. 45, 67, 68, [70] [71] [72] 
Conclusion and Future Perspective
Two fundamental stem cell populations in tumors (i) resident CSCs and (ii) tumor homing MSCs, exist to provide functional heterogeneity by regulating tumor hallmarks. 17, 43, 73 Exosomes, being nano-scale structures in nature can reach to most tumor territories including hypoxic regions, intact blood vessel barriers, and systemic circulation in body. All these features make them a vital component of tumor biology. Indeed, exosomes secreted by both MSCs and CSCs propose a bigger challenge to understand tumor growth, and its complex microenvironment. MSC-exo have antagonistic roles in tumor progression similar to MSCs themselves. It could be speculated that due to tumor-dependent functions, MSC-exo can exert contrasting effects. However, since miRNA export in exosome and exosome quality control during their harvesting/sample preparation is not well understood, it is not unlikely that these experimental issues can also confound the study and yield differential results. It is therefore required to develop quality control/standard operating protocols in exosome isolation techniques to reap the benefits. Additionally, the conflicting data may also be due to variable timing of MSC growth, composition of culture media, and passages of MSC used. 18, 74 In line, is it shown that MSCs ageing significantly alters telomerase length, differentiation potential, proliferation index, and secretome along with the induction of a senescent phenotype in culture. 75, 76 Moreover, changes in oxygen tension can modulate paracrine functions of MSCs 77 and it is likely MSC grown under variable oxygen tensions might have exosome cargo differences. Therefore, it is crucial to use MSCs at low passage, and controlled growth conditions to obtain consistent results with their exosomes. Similarly, growth time for MSC exosome isolation, and quality of exosome depleted serum in MSC growth both can contribute to obtaining variable data. Moreover, source of MSCs (adipose vs. bone marrow) may also change their exosome cargo composition and hence, influence MSC-exo effects on tumors cells. For example, adipose derived MSCs kill brain tumor cells, 78 whereas, bone marrow derived MSCs are actively recruited by glioma cells for tumor promoting functions. 79 Hence, a comparison between differently sourced MSC-exo systems for their effects on tumor cells is not rationally valid. Importantly, it would be interesting to know how MSC-exo interact with resident tumor-associated immune cells and what effects they might have on regulatory T cells during immune check-point kinase inhibitors treatment. Unlike, MSC-exo, CSC-exo are generally tumor promoting in nature. Although, CSC-exo are not much studied yet their ability to transfer various CSC-specific proteins and transcription factors to neighboring cells adds up to greater implications in tumor heterogeneity maintenance. It would be worth investigating if exosomal export of CSC-specific factors can induce CSC-like subpopulations in adjacent non-CSC stromal/tumor cells. To measure the effects of CSC-exo mediated tumor or stromal cell reprogramming one can use various functional assays, for example, stemness gene expression or sphere formation assay, ability to induce tumor in animals even at low cell number, and by estimating in vivo/in vitro invasion potential of CSC-exo primed stromal cells. The potential implications of understanding such a phenomenon would be in developing novel therapeutic strategies where blocking of exosome secretion can be combined with conventional therapies. Nevertheless, potential off-target effects of such inhibition may act as a double edge sword. Lastly, exosomes can also remodel stroma either by synthesis or degrading extracellular matrix (ECM) proteins via receptor-ligand mediated interactions. [80] [81] [82] ECM modulation of exosomes can create pre-metastatic niches, and contribute to enhanced invasion potential of cancer cells. Therefore, identifying and targeting such interactions could also be vital in understanding tumor progression. Finally, we can speculate that tumor stem cell (MSCs, CSCs) derived exosomes are multifaceted regulators and can bring us closer to clinically treating cancers.
